NZ585217A - Fviii peptides and their use in tolerising haemophiliacs - Google Patents

Fviii peptides and their use in tolerising haemophiliacs

Info

Publication number
NZ585217A
NZ585217A NZ585217A NZ58521708A NZ585217A NZ 585217 A NZ585217 A NZ 585217A NZ 585217 A NZ585217 A NZ 585217A NZ 58521708 A NZ58521708 A NZ 58521708A NZ 585217 A NZ585217 A NZ 585217A
Authority
NZ
New Zealand
Prior art keywords
fviii peptides
peptide
peptides
tolerising
haemophiliacs
Prior art date
Application number
NZ585217A
Other languages
English (en)
Inventor
David Wraith
Original Assignee
Apitope Technology Bristol Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apitope Technology Bristol Ltd filed Critical Apitope Technology Bristol Ltd
Publication of NZ585217A publication Critical patent/NZ585217A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ585217A 2007-12-04 2008-12-03 Fviii peptides and their use in tolerising haemophiliacs NZ585217A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0723712.6A GB0723712D0 (en) 2007-12-04 2007-12-04 Peptides
PCT/GB2008/003996 WO2009071886A1 (en) 2007-12-04 2008-12-03 Fviii peptides and their use in tolerising haemophiliacs

Publications (1)

Publication Number Publication Date
NZ585217A true NZ585217A (en) 2012-11-30

Family

ID=38982965

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ585217A NZ585217A (en) 2007-12-04 2008-12-03 Fviii peptides and their use in tolerising haemophiliacs

Country Status (25)

Country Link
US (1) US8445448B2 (enExample)
EP (1) EP2227488B3 (enExample)
JP (2) JP5501245B2 (enExample)
KR (1) KR101519840B1 (enExample)
CN (2) CN103709234B (enExample)
AU (1) AU2008332968B2 (enExample)
BR (1) BRPI0820143A2 (enExample)
CA (2) CA2707559C (enExample)
CY (1) CY1115168T1 (enExample)
DK (1) DK2227488T6 (enExample)
EA (1) EA019370B1 (enExample)
EC (1) ECSP10010327A (enExample)
ES (1) ES2458315T7 (enExample)
GB (1) GB0723712D0 (enExample)
HR (1) HRP20140344T4 (enExample)
IL (1) IL205780A (enExample)
MX (1) MX2010006084A (enExample)
MY (1) MY150995A (enExample)
NZ (1) NZ585217A (enExample)
PL (1) PL2227488T6 (enExample)
PT (1) PT2227488E (enExample)
SI (1) SI2227488T1 (enExample)
UA (1) UA101003C2 (enExample)
WO (1) WO2009071886A1 (enExample)
ZA (1) ZA201002997B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030062321A (ko) 2000-08-21 2003-07-23 아피토프 테크놀러지 (브리스톨) 리미티드 펩티드 선별 방법
GB0801513D0 (en) * 2008-01-28 2008-03-05 Circassia Ltd Peptides from factor VIII
US8329871B2 (en) * 2008-06-24 2012-12-11 Octapharma Ag Process of purifying coagulation factor VIII
GB0908515D0 (en) * 2009-05-18 2009-06-24 Apitope Technology Bristol Ltd Peptide
US20120135917A1 (en) * 2009-06-16 2012-05-31 Eisaku Yoshihara Anti-Gram Negative Bacteria Agent
PL3260132T3 (pl) * 2010-10-27 2022-08-08 Takeda Pharmaceutical Company Limited Peptydy fviii do wywoływania tolerancji immunologicznej oraz immunodiagnostyki
EA038705B1 (ru) 2012-01-12 2021-10-07 Биовератив Терапьютикс Инк. Способы снижения иммуногенности фактора свёртывания крови viii у пациентов, получающих лечение фактором viii
CN104903347B (zh) * 2012-11-12 2020-02-21 艾匹托普国际股份有限公司 肽
GB201314052D0 (en) 2013-08-06 2013-09-18 Apitope Int Nv Peptides
MX2018006789A (es) 2015-12-03 2019-02-13 Juno Therapeutics Inc Receptores quimericos modificados y composiciones y metodos relacionados.
CA3044838A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
US12077607B2 (en) * 2021-09-23 2024-09-03 University Of Utah Research Foundation Functional and therapeutic effects of PAR4 cleavage by cathepsin G

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990015615A1 (en) * 1989-06-20 1990-12-27 Scripps Clinic And Research Foundation The phospholipid binding domain of factor viii
US6132729A (en) * 1997-01-22 2000-10-17 Board Of Regents, The University Of Texas System Combined tissue factor and chemotherapeutic methods and compositions for coagulation and tumor treatment
KR20030062321A (ko) 2000-08-21 2003-07-23 아피토프 테크놀러지 (브리스톨) 리미티드 펩티드 선별 방법
US20040096456A1 (en) * 2000-12-01 2004-05-20 Conti-Fine Bianca M Method to treat hemophilia
PL362324A1 (en) * 2001-02-19 2004-10-18 Merck Patent Gmbh Artificial fusion proteins with reduced immunogenicity
AU2002312660A1 (en) * 2001-05-31 2002-12-16 D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
MXPA04010061A (es) * 2002-04-18 2004-12-13 Merck Patent Gmbh Factor viii modificado.
CN102816241B (zh) * 2004-02-09 2015-07-22 人类基因科学公司 清蛋白融合蛋白
WO2006003183A1 (de) 2004-07-02 2006-01-12 Alois Jungbauer Peptide zur blockierung von fviii-inhibitoren
IL229645A0 (en) * 2013-11-26 2014-03-31 Omrix Biopharmaceuticals Ltd A dry bandage containing thrombin and pectin

Also Published As

Publication number Publication date
BRPI0820143A2 (pt) 2015-05-12
ZA201002997B (en) 2011-07-27
CN101889024B (zh) 2014-04-23
JP6063402B2 (ja) 2017-01-18
JP2014088440A (ja) 2014-05-15
CA3005013C (en) 2021-11-16
CA2707559C (en) 2018-07-03
GB0723712D0 (en) 2008-01-16
UA101003C2 (uk) 2013-02-25
PL2227488T3 (pl) 2014-07-31
ES2458315T3 (es) 2014-04-30
ECSP10010327A (es) 2010-09-30
SI2227488T1 (sl) 2014-06-30
CN103709234B (zh) 2017-01-18
AU2008332968B2 (en) 2014-03-20
EA201070681A1 (ru) 2010-10-29
IL205780A0 (en) 2010-11-30
EP2227488B1 (en) 2014-01-22
CA3005013A1 (en) 2009-06-11
PL2227488T6 (pl) 2015-04-30
MX2010006084A (es) 2010-06-23
MY150995A (en) 2014-03-31
HRP20140344T1 (en) 2014-05-09
KR20100087346A (ko) 2010-08-04
JP5501245B2 (ja) 2014-05-21
CY1115168T1 (el) 2016-12-14
CN101889024A (zh) 2010-11-17
HK1144292A1 (en) 2011-02-11
ES2458315T7 (es) 2015-02-18
JP2011505414A (ja) 2011-02-24
KR101519840B1 (ko) 2015-05-18
EP2227488A1 (en) 2010-09-15
PT2227488E (pt) 2014-04-21
AU2008332968A1 (en) 2009-06-11
CN103709234A (zh) 2014-04-09
DK2227488T6 (en) 2015-02-16
HRP20140344T4 (hr) 2015-07-31
WO2009071886A1 (en) 2009-06-11
US8445448B2 (en) 2013-05-21
EA019370B1 (ru) 2014-03-31
EP2227488B3 (en) 2014-11-19
IL205780A (en) 2015-06-30
US20100323966A1 (en) 2010-12-23
CA2707559A1 (en) 2009-06-11
DK2227488T3 (da) 2014-04-22

Similar Documents

Publication Publication Date Title
MX2010006084A (es) Peptidos del factor viii y su uso en la tolerizacion de hemofilicos.
EA201592264A1 (ru) Композиции, которые индуцируют хелперное действие т-клеток
NZ595707A (en) Cancer antigen helper peptide
EA201070271A1 (ru) Пептиды для получения вакцины
WO2008121615A3 (en) Antibody formulation
EA201000207A1 (ru) Новые иммуногенные эпитопы для иммунотерапии
EP2666784A3 (en) Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
WO2004081028A3 (en) Allergen peptide fragments and use thereof
UA100372C2 (ru) Выделенный пептид, способный индуцировать цитотоксические т-клетки, и его применение в качестве вакцины
PL1620456T3 (pl) Peptydy antygenu związanego z nowotworem HLA-A2 i kompozycje
PH12016500218A1 (en) Peptides
ATE552276T1 (de) Modifizierter anti-cd52-antikörper
MY168207A (en) Fviii-derived peptides
ATE412671T1 (de) Modifizierter faktor viii
EA201171001A1 (ru) Пептиды трав для вакцины
PH12015501033A1 (en) Peptides
IL184609A0 (en) Compositions containing an antigen and an adjuvent peptide
MX2011004176A (es) Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo.
DE602005012686D1 (de) Zusammensetzungen aus demethylierenden mitteln als verstärker der immuntherapie zur behanldung von cngen und behandlungsverfahren dafür
NZ605799A (en) Wdrpuh epitope peptides and vaccines containing the same
WO2007097828A3 (en) Method for identifying and validating dominant t helper cell epitopes using an hla-dm-assisted class ii binding assay
TH130487A (th) เพปไทด์ที่อนุพัทธ์มาจากแฟคเตอร์ viii
NZ601354A (en) Peptide adjuvants
SI1485719T1 (sl) Peptidni epitopi, ki so skupni antigenom iste multigenske druĹľine

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: APITOPE INTERNATIONAL NV, BE

Free format text: OLD OWNER(S): APITOPE TECHNOLOGY (BRISTOL) LIMITED

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 03 DEC 2015 BY AJ PARK

Effective date: 20130627

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 DEC 2016 BY CPA GLOBAL

Effective date: 20151030

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 DEC 2017 BY CPA GLOBAL

Effective date: 20161108

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 DEC 2018 BY CPA GLOBAL

Effective date: 20171102

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 DEC 2019 BY CPA GLOBAL

Effective date: 20181108

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 DEC 2020 BY RENEWALS TEAM

Effective date: 20191127

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 DEC 2021 BY ENVOY

Effective date: 20210601

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 DEC 2022 BY RENEWALS TEAM

Effective date: 20211202

ASS Change of ownership

Owner name: WORG PHARMACEUTICALS (HANGZHOU) CO., LTD., CN

Effective date: 20220303

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 DEC 2023 BY AJ PARK

Effective date: 20221208

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 DEC 2024 BY DENNEMEYER + CO. S.A R.L.

Effective date: 20231123

LAPS Patent lapsed